KinergyCare is a Virginia-based startup and a Virginia Bio member that is requesting feedback from this community on a care coaching and coordination approach that focuses on the needs of patients with cardiovascular disease. We’re pioneering a new approach that combines patient data on health capabilities with a personalized intervention based on behavioral science. The result should be a more personalized clinical intervention and coaching approach that better ensures lasting behavioral change. We’re looking to talk with stakeholders such as cardiologists, nurses, care management teams, and administrators to learn more about the unmet needs. This outreach is part of our participation in the Spring cohort of the Roanoke Acceleration and Mentoring Program (RAMP), so we would really appreciate any help. Please help us by filling in this brief, 10 question survey. Also, if you have some guidance or can connect us with someone in your network that fits the above roles please contact KinergyCare CEO Art Spivy at aspivy@kinergycare.com or (571) 277-5373. Thanks for your help!
News
Recent News
10/13/2025
InBio Secures $3.5 Million NIH Grant to Advance Allergy Research
InBio, a global leader in allergy research, was recently awarded a $3.5 million R01 grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This funding supports a groundbreaking initiative to develop innovative immunotherapeutic tools targeting allergens from house dust mites, cats, and dogs—major contributors to …
10/09/2025
AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
AstraZeneca announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at …
10/09/2025
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the successful completion of the analytical validation of a cheek swab collection method for testing patients for both clinical trial usage as well as future commercial application. This major step marks a …